Who are Talzenna's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pharmacokinetics, Dosage of Niraparib, Olaparib Treatment D, Active comparator: Niraparib, Olaparib tablet, Saruparib (AZD5305), Active Comparator: Olaparib tablets.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/talazoparib-tosylate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Talzenna — Competitive Intelligence Brief

Talzenna (talazoparib-tosylate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Poly(ADP-Ribose) Polymerase Inhibitor. Area: Oncology.

marketed Poly(ADP-Ribose) Polymerase Inhibitor PARP1, PARP2 Oncology Live · refreshed every 30 min

Target snapshot

Talzenna (talazoparib-tosylate) — Pfizer. Talazoparib inhibits PARP enzymes, causing DNA damage and cell death in cancer cells with DNA repair defects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Talzenna TARGET	talazoparib-tosylate	Pfizer	marketed	Poly(ADP-Ribose) Polymerase Inhibitor	PARP1, PARP2	2018-01-01
Pharmacokinetics, Dosage of Niraparib	Pharmacokinetics, Dosage of Niraparib	Hospices Civils de Lyon	marketed	PARP inhibitor	PARP1, PARP2
Olaparib Treatment D	Olaparib Treatment D	AstraZeneca	marketed	PARP inhibitor	PARP1, PARP2
Active comparator: Niraparib	Active comparator: Niraparib	Tesaro, Inc.	phase 3	PARP inhibitor	PARP1, PARP2
Olaparib tablet	Olaparib tablet	Fondazione Ricerca Traslazionale	phase 3	PARP inhibitor	PARP1, PARP2
Saruparib (AZD5305)	Saruparib (AZD5305)	AstraZeneca	phase 3	PARP inhibitor	PARP1, PARP2
Active Comparator: Olaparib tablets	Active Comparator: Olaparib tablets	AstraZeneca	phase 3	PARP inhibitor	PARP1, PARP2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-07-27 — Talzenna · 8420650 · US
2029-07-27 — Talzenna · 9820985 · US
2029-07-27 — Talzenna · 10780088 · US
2029-10-19 — Talzenna · 8012976 · US
2031-10-20 — Talzenna · 8735392 · US
2031-10-20 — Talzenna · 10189837 · US

Sponsor landscape (Poly(ADP-Ribose) Polymerase Inhibitor class)

Pfizer · 2 drugs in this class
GSK · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Talzenna — Competitive Intelligence Brief. https://druglandscape.com/ci/talazoparib-tosylate. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab